

Yann Neuzillet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9262022/publications.pdf>

Version: 2024-02-01

106
papers

6,999
citations

87723

38
h-index

66788

78
g-index

178
all docs

178
docs citations

178
times ranked

6893
citing authors

#	ARTICLE	IF	CITATIONS
1	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.	0.4	1
2	Small intestinal submucosa xenograft to manage lower urinary tract prostheses perforation: a new path?. <i>International Urogynecology Journal</i> , 2022, 33, 627-635.	0.7	1
3	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	0.9	158
4	Long-term survival benefit from dual kidney transplantation using kidneys from donors with very extended criteria—a French cohort between 2002 and 2014. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 982-990.	0.4	1
5	Online Public Interest in Urological Cancers During the COVID-19 Pandemic: What Can “Dr. Google” Teach Us?. <i>European Urology Open Science</i> , 2022, 37, 73-79.	0.2	9
6	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	0.8	22
7	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology “Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	1.6	7
8	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	0.9	1,152
9	A review of new hormonal therapies for prostate cancer in black men: is there enough data?. <i>BMC Cancer</i> , 2021, 21, 61.	1.1	4
10	PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study. <i>World Journal of Urology</i> , 2021, 39, 2945-2951.	1.2	5
11	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
12	Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 1811-1823.	1.1	12
13	Risk factors associated with positive surgical margins™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	1.2	22
14	The impact of carcinoma in situ in ureteral margins during radical cystectomy: A case-controlled study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 497.e1-497.e8.	0.8	1
15	Management of long ureteral stenosis: Alternatives to indwelling ureteral stents. <i>Progres En Urologie</i> , 2021, 31, 598-604.	0.3	2
16	Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy. <i>Asian Journal of Andrology</i> , 2021, 23, 370.	0.8	1
17	Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy. <i>Asian Journal of Andrology</i> , 2021, 23, 520.	0.8	2
18	Impact of carcinoma in situ on survival of patients treated by adjuvant chemotherapy after cystectomy. <i>Progres En Urologie</i> , 2021, 32, 53-53.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvic/ureteric System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. <i>European Urology Focus</i> , 2021, 7, 1075-1083.	1.6	5
20	Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie. <i>Cancers</i> , 2021, 13, 6070.	1.7	2
21	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 295-303.e3.	0.9	12
22	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	2.6	61
23	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer: An International Collaborative Multi-stakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
24	Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer. <i>Scientific Reports</i> , 2020, 10, 16145.	1.6	5
25	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. <i>World Journal of Urology</i> , 2020, 39, 4055-4065.	1.2	11
26	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? <i>European Urology</i> , 2020, 78, 682-687.	0.9	57
27	PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 549-560.	2.0	36
28	European Association of Urology Guidelines on Primary Urethral Carcinoma: 2020 Update. <i>European Urology Oncology</i> , 2020, 3, 424-432.	2.6	28
29	Prognosis of patients receiving induction chemotherapy for locally advanced or lymph node metastatic bladder cancer. <i>Journal of Clinical Urology</i> , 2020, 13, 425-436.	0.1	1
30	Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study. <i>Prostate</i> , 2019, 79, 1640-1646.	1.2	4
31	Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. <i>PLoS ONE</i> , 2019, 14, e0211721.	1.1	17
32	Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. <i>European Radiology</i> , 2019, 29, 4286-4293.	2.3	48
33	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer: an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	0.6	96
34	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019, 108, 111-119.	1.3	16
35	Recurrent activating mutations of PPAR γ 3 associated with luminal bladder tumors. <i>Nature Communications</i> , 2019, 10, 253.	5.8	44
36	Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial). <i>Prostate</i> , 2019, 79, 272-280.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. <i>Hormones and Cancer</i> , 2019, 10, 36-44.	4.9	23
38	PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk non-muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4550-4550.	0.8	3
39	ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naïve patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4589-TPS4589.	0.8	6
40	Management of renal transplant urolithiasis: a multicentre study by the French Urology Association Transplantation Committee. <i>World Journal of Urology</i> , 2018, 36, 105-109.	1.2	17
41	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
42	Quelles ordonnances l'urologue doit-il rédiger pour initier et suivre une immunothérapie?. <i>Progrès En Urologie - FMC</i> , 2018, 28, F51-F54.	0.2	0
43	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	0.9	1,241
44	Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. <i>BJU International</i> , 2017, 120, 12-24.	1.3	63
45	Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score. <i>Urologia Internationalis</i> , 2017, 99, 156-161.	0.6	15
46	Sexual steroids in serum and prostatic tissue of human non-cancerous prostate (STERPROSER trial). <i>Prostate</i> , 2017, 77, 1512-1519.	1.2	13
47	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016, 27, 1311-1316.	0.6	49
48	What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. <i>World Journal of Urology</i> , 2016, 34, 617-624.	1.2	15
49	Quality of life outcomes after neobladder and ileal conduit following cystectomy for bladder cancer using a validated bladder-specific instrument: A prospective multi-institutional study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 359-359.	0.8	0
50	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685.	5.1	229
51	Trends in Renal Function After Radical Cystectomy and Ileal Conduit Diversion: New Insights Regarding Estimated Glomerular Filtration Rate Variations. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e139-e144.	0.9	18
52	Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 589-594.	1.4	125
53	Obesity and hypogonadism are associated with an increased risk of predominant Gleason 4 pattern on radical prostatectomy specimen. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2015, 22, 101-9.	0.3	5
54	Positive surgical margins after radical prostatectomy: What should we care about?. <i>World Journal of Urology</i> , 2015, 33, 1973-1978.	1.2	17

#	ARTICLE	IF	CITATIONS
55	Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 382-387.	2.0	26
56	Characteristics of undetected prostate cancer on diffusion-weighted MR Imaging at 3-Tesla with a b-value of 2000s/mm ² : Imaging-pathologic correlation. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 923-929.	1.8	12
57	Long-term follow-up of TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 20.e1-20.e7.	0.8	13
58	Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study. <i>BJU International</i> , 2015, 115, 87-93.	1.3	19
59	Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. <i>BJU International</i> , 2014, 114, 733-740.	1.3	62
60	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. <i>Cell Reports</i> , 2014, 9, 1235-1245.	2.9	181
61	Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1724-1730.	0.5	27
62	Assessment of diagnostic gain with hexaminolevullinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1135-1140.	0.8	25
63	Effects of Adenosine Monophosphate Used in Combination with Arginine on Female Rabbit Corpus Cavernosum Tissue. <i>Sexual Medicine</i> , 2014, 2, 1-7.	0.9	0
64	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	5.8	304
65	Long-Term Women-Reported Quality of Life After Radical Cystectomy and Orthotopic Ileal Neobladder Reconstruction. <i>Annals of Surgical Oncology</i> , 2014, 21, 1398-1404.	0.7	32
66	Clinicopathological Characteristics of Incidental Prostate Cancer Discovered from Radical Cystoprostatectomy Specimen: A Multicenter French Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 684-690.	0.7	22
67	Landmarks in non-muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 476-480.	1.9	23
68	Cáncer de riñón en el paciente dializado y en el paciente trasplantado. <i>EMC - Urología</i> , 2014, 46, 1-10.	0.0	0
69	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 207-213.	1.4	23
70	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e19-e27.	0.9	31
71	A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction. <i>Andrology</i> , 2013, 1, 223-228.	1.9	30
72	Influence of preoperative hydronephrosis on the outcome of urothelial carcinoma of the upper urinary tract after nephroureterectomy: the results from a multi-institutional French cohort. <i>World Journal of Urology</i> , 2013, 31, 83-91.	1.2	20

#	ARTICLE	IF	CITATIONS
73	Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: A prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. <i>European Journal of Cancer</i> , 2013, 49, 431-438.	1.3	41
74	Comment suivre un schéma d'instillation du BCG en toute sécurité en 2013?. <i>Progrès En Urologie - FMC</i> , 2013, 23, F40-F46.	0.2	0
75	Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case-control study. <i>BJU International</i> , 2013, 111, 1253-1260.	1.3	36
76	Indication and timing of cystectomy in high-risk bladder cancer. <i>Current Opinion in Urology</i> , 2012, 22, 427-431.	0.9	7
77	Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. <i>British Journal of Cancer</i> , 2012, 106, 1083-1088.	2.9	84
78	Concentration and Chain Length of Polyethylene Glycol in Islet Isolation Solution: Evaluation in a Pancreatic Islet Transplantation Model. <i>Cell Transplantation</i> , 2012, 21, 2079-2088.	1.2	6
79	De Novo Kidney Graft Tumors: Results From a Multicentric Retrospective National Study. <i>American Journal of Transplantation</i> , 2012, 12, 3308-3315.	2.6	82
80	Patterns of local recurrence after radical cystectomy in a contemporary series of patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2012, 30, 821-826.	1.2	21
81	Influence of Positive Surgical Margin Status After Radical Nephroureterectomy on Upper Urinary Tract Urothelial Carcinoma Survival. <i>Annals of Surgical Oncology</i> , 2012, 19, 3613-3620.	0.7	72
82	French results of the ARESC Study: Clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. <i>Médecine Et Maladies Infectieuses</i> , 2012, 42, 66-75.	5.1	31
83	A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. <i>PLoS ONE</i> , 2012, 7, e48993.	1.1	47
84	Assessment of Oncologic Control Obtained After Open Versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinomas (UUT-UCs): Results from a Large French Multicenter Collaborative Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 301-308.	0.7	84
85	<i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> -mutated urothelial bladder carcinoma. <i>Journal of Pathology</i> , 2012, 227, 315-324.	2.1	90
86	Effects of nucleotides adenosine monophosphate and adenosine triphosphate in combination with L-arginine on male rabbit corpus cavernosum tissue. <i>Journal of Developmental and Physical Disabilities</i> , 2012, 35, 860-866.	3.6	17
87	Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. <i>BJU International</i> , 2012, 110, 1134-1141.	1.3	105
88	Perivesical fat invasion in bladder cancer: implications for prognosis comparing pT2b, pT3a and pT3b stages and consequences for adjuvant chemotherapy indications. <i>BJU International</i> , 2012, 110, 1736-1741.	1.3	21
89	The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. <i>BJU International</i> , 2012, 110, E1035-40.	1.3	28
90	Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities?. <i>BJU International</i> , 2012, 110, E570-3.	1.3	44

#	ARTICLE	IF	CITATIONS
91	Quâ€™attendre dâ€™un dosage de la testostÃ©ronÃ©mie chez un patient ayant un cancer de prostate? ProgrÃ©s, En Urologie - FMC, 2011, 21, F80-F85.	0,2	0
92	Idiopathic Infantile Bladder Lithiasis from Roman Antiquity. Urology, 2011, 78, 1-2.	0.5	11
93	High Incidence of Predominant Gleason Pattern 4 Localized Prostate Cancer is Associated With Low Serum Testosterone. Journal of Urology, 2011, 186, 1400-1405.	0.2	40
94	The Z-shaped ileal neobladder after radical cystectomy: an 18 years experience with 329 patients. BJU International, 2011, 108, 596-602.	1.3	20
95	Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population. European Urology, 2011, 60, 366-373.	0.9	82
96	Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study. Annals of Surgical Oncology, 2011, 18, 3833-3838.	0.7	11
97	Preoperative low serum testosterone levels are associated with tumor aggressiveness in radical prostatectomy treated cancer patients. Hormone Molecular Biology and Clinical Investigation, 2010, 2, 191-201.	0.3	8
98	Effectiveness of a cranberry (<i>Vaccinium macrocarpon</i>) preparation in reducing asymptomatic bacteriuria in patients with an ileal enterocystoplasty. Scandinavian Journal of Urology and Nephrology, 2010, 44, 165-168.	1.4	23
99	Prognosis factors in localised and metastatic renal cell carcinoma. Oncologie, 2009, 11, 260-266.	0.2	0
100	Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. International Journal of Urology, 2009, 16, 855-861.	0.5	5
101	Morbidity of Retropubic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Multicenter Study from Renal Transplantation Committee of French Urological Association. Urology, 2008, 72, 1366-1370.	0.5	42
102	Prostate cancer in renal transplant recipients. Nephrology Dialysis Transplantation, 2008, 23, 2374-2380.	0.4	64
103	Effects of the Molecular Weight of Peg Molecules (8, 20 and 35 KDA) on Cell Function and Allograft Survival Prolongation in Pancreatic Islets Transplantation. Transplantation Proceedings, 2006, 38, 2354-2355.	0.3	14
104	De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer, 2005, 103, 251-257.	2.0	86
105	Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. Urology, 2005, 66, 1181-1185.	0.5	74
106	Accuracy and Clinical Role of Fine Needle Percutaneous Biopsy With Computerized Tomography Guidance of Small (Less Than 4.0 Cm) Renal Masses. Journal of Urology, 2004, 171, 1802-1805.	0.2	288